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Abstract 
Metformin is a dimethyl biguanide oral
anti-hyperglycemic agent. Lactic acidosis due
to metformin is a fatal metabolic condition
that limits its use in patients in poor clinical
condition, consequently reducing the number
of patients who benefit from this medication.
In a double blind randomized clinical trial, we
investigated 200 type 2 diabetic patients after
coronary artery bypass surgery in the open
heart ICU of the Mazandaran Heart Center,
and randomly assigned them to equal inter-
vention and control groups. The intervention
group received regular insulin infusion along
with 2 metformin 500 mg tablets every twelve
hours, while the control group received only
intravenous insulin with 2 placebo tablets
every twelve hours. Lactate level, pH, base
excess, blood glucose and serum creatinine
were measured over five 12 h periods, with
data averaged for each period. The primary
outcome in this study was high lactate levels.
Comparison between the 2 groups was made
by independent Student’s t-test. To compare
changes in multiple measures in each group
and analysis of group interaction, a repeated
measurement ANOVA test was used.
There was no significant difference
between the 2 groups regarding pH, base
excess, or bicarbonate intake (P>0.05). No
patient showed lactic acidosis in either group.
Lactate levels were 23.0 vs 23.4 in the insulin-
metformin and insulin only groups when the
study was started, respectively. At the end of
the study, those levels were 18.7 vs 18.9,
respectively. In addition, the ANOVA repeated
measurement test did not show a significant
difference in terms of changes in the amount
of lactate level between the 2 groups during
the five measurement tests of the study period
(P>0.05).
High-dose metformin (1,000 mg twice daily
with insulin) does not cause lactic acidosis in
type 2 diabetic patients after coronary artery
bypass surgery.
Introduction
Coronary artery bypass surgery (CABG) is
the most common heart surgery. In the United
States, 515,000 patients undergo coronary
artery bypass surgery (CABG) each year; about
28% of them have diabetes.1
Hyperglycemia (blood glucose over 200
mg/dL) is common in patients in a poor clini-
cal condition. This causes more infection,
ischemic events, renal and neurological com-
plications, and higher mortality.2,3 The main
mechanism of increased blood glucose in this
condition is insulin resistance (IR); therefore,
insulin is considered to be the main drug for
treatment of hyperglycemia. However, insulin
accelerates the transfer of potassium and
magnesium into the cells that may lead to
hypokalemia and hypomagnesia.4,5 In addi-
tion, due to insulin resistance and insulin
induced hypoglycemia, the use of products
such as metformin, which does not cause
hypoglycemia, is recommended for blood glu-
cose control in patients with insulin resist-
ance.4
Metformin was introduced in the United
States in 1995. It is a dimethyl biguanide oral
anti-hyperglycemic drug that reduces overall
mortality in type 2 diabetes.6 Metformin
reduces gluconeogenesis and glycogenolysis,
and increases sensitivity of insulin receptors
through multiple mechanisms. In addition, it
reduces the level of serum lipids and lipopro-
teins. In particular, it reduces stroke (41%)
and heart attacks (39%).7
Metformin has different mechanisms of
action from other anti-hyperglycemic drugs
and does not lead to a severe drop in the blood
glucose level of diabetic patients.7 Between
the years 1985 to 2001, 66 cases of metformin-
associated lactic acidosis (MALA) were report-
ed by the FDA and 48 cases by the Australian
Adverse Drug Reactions Advisory Committee
(ADRAC).8 MALA is a fatal metabolic condition
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that limits metformin use in patients in poor
clinical condition.9 These restrictions consid-
erably reduce the number of patients who
could benefit from this advantageous drug.10
However, Salpeter et al.6 have estimated the
incidence of lactic acidosis in type 2 diabetic
metformin users to be less than non-met-
formin users (0.0043% vs 0.0054%). These
results are similar to those of Stang et al.
(0.002-0.009% vs 0.009%).5 This clinical trial
was performed to determine whether met-
formin can create lactic acidosis in type 2 dia-
betic patients after CABG surgery. Whereas
previous studies have taken a descriptive or
retrospective approach with different times/
dose of metformin, to our knowledge, this is
the first clinical trial studying the effect of
metformin administration in such patients.
Materials and Methods
In this double blind randomized clinical
trial, 200 type 2 diabetic patients were studied
following CABG surgery in the open heart ICU
of the Mazandaran Heart Center. Approval
from the Ethics Committee of Mazandaran
University of Medical Sciences and informed
consent from patients were obtained. Patients
were randomly and simultaneously assigned to
2 groups; 100 patients received insulin and 100
received insulin-metformin.
Inclusion criteria were: age between 35 to
75 years, type 2 diabetes, non-emergency
CABG surgery, the use of cardiopulmonary
pump during the operation and hemodynamic
stability (MAP > 60, lack of dangerous dys-
rhythmia and heart rate between 50 to 100). 
We excluded patients with any kind of liver
disorder (SGPT and SGOT more than 75), renal
dysfunction (serum creatinine more than 1.5
mg/dL in 2 consecutive tests), heart failure
(ejection fraction ratio less than 30%), and the
use of any contrast or history of angiography
within two days before the operation.
Medication would be interrupted and patients
would leave the study if at any time during the
study the following events were recorded:
serum lactate level more than 45 mg/dL (5
mmol/L) or had values which increased more
than 18 mg/dL (2 mmol/L) compared to previ-
ous levels, pH less than 7.25 or serum base
excess (BE) of less than -6 mmol/L, mean arte-
rial oxygen pressure less than 60 mmHg in two
consecutive Arterial Blood Gas (ABG) tests,
potassium drops of less than 3 meq/L, nausea
and vomiting, use of metformin metabolism
inhibitors such as amiodarone and cimetidine,
use of high-dose inotrope drugs more than 3 h
after extubation and need for reoperation for
any reason. Patients who qualified for study
entry were randomly assigned to one of these
groups.
Insulin group: regular insulin infusion
based on the center protocol with 2 placebo
tablets (Sari pharmaceutical laboratory, Iran)
every 12 h. Insulin-metformin group: regular
insulin infusion based on the center protocol
with 2 metformin tablets 500 mg (Aria, Iran)
every 12 h.
Metformin or placebo were prescribed 3 h
after extubation by oral administration and in
the absence of oral tolerance through a naso-
gastric tube. All oral anti-hyperglycemic drugs
were discontinued two days before the surgery
in all patients and subsequent blood glucose
levels were controlled with insulin. There was
no difference in onset of intervention or
patient diet before and after surgery between
the 2 groups (diabetic and cardio diet based on
hospital routine). Patients were placed in
treatment protocols for 60 h during which
blood glucose, lactate, pH and BE were meas-
ured every 2 h and creatinine was measured
daily. The study was divided into 5 stages and
the mean 12 h period values were calculated.
Blood glucose, lactate, pH and BE were meas-
ured by advanced Blood Gas machine GEM
3000 (Instrumen tation Laboratory, MA, USA)
using future pulse medical company cartridge.
Serum creatinine was measured by Auto
Analyzer Ebra XL640 model and Pars Company
Cartridge. This was a double blind study and
none of the patients, physicians, nurses or lab-
oratory staff was aware of the type of treatment
received. 
Primary outcome in this study was blood lac-
tate levels. An acceptable range of arterial
blood lactate level is 4.5-13.5 mg/dL. Blood glu-
cose level, pH and BE were assessed as second-
ary outcomes. In this study, acidosis and hypo-
glycemia were considered to be complications.
After collecting and classifying data, statistical
analyses were carried out by SPSS 16 software.
Qualitative variables were evaluated with the
χ2test. After controlling the normal distribu-
tion of numerical variables by the Kolmogorov-
Smirnov test, an independent student's t-test
was calculated to compare the two groups. To
compare changes in multiple measurements
in each group and to analyze group interaction,
a repeated measurement ANOVA test was
used. In all statistical tests, the significance
level was considered to be 0.05.
Results
Two hundred patients were entered in this
clinical trial; 100 patients in the insulin group
and 100 patients in the insulin-metformin
group (using an equal randomized allocation).
Ten patients were excluded during the project
and data from 190 patients were analyzed
(Figure 1).
Forty-six of 96 patients (52.1%) among the
insulin group and 50 of 94 patients (46.8%)
among the insulin-metformin group were men
but the difference was not statistically signifi-
cant (P>0.05).
Also there was no statistically significant
difference in the basic and clinical characteris-
tics between the 2 groups (Table 1).
Lactic acidosis was not observed in either of
the study arms. In patients receiving insulin,
at baseline the serum lactate level was
23.4±10.1 (mg/dL), while at the end of study, it
reached 18.9±5.9 (a 19% reduction). Similarly,
an approximately 19% reduction in serum lac-
tate level was seen in the metformin group
(Figure 2).
Changes in pH and BE were similar in both
groups with no statistically significant differ-
ence (F(1, 187)=0.286; P=0.853 for pH and
F(1, 187)=0.159; P=0.932) for BE (Figure 3).
Average consumed bicarbonate during the
study was 6.77 meq (95%CI: 4.07 to 9.470) in
the insulin group and 6.91meq (95%CI: 3.97 to
Table 1. Pre-operative patient characteristics.
Insulin group Insulin-metformin P
(n=96) Group (n=94) (t-test)
Mean 95% CI Mean 95% CI
Age (Y) 60.5 59.2 to 61.8 59.8 58.3 to 61.2 0.435
Weight (kg) 66.4 64.4 to 68.4 67.8 65.7 to 70.0 0.350
Height (m) 1.62 1.60 to 1.64 1.63 1.61 to 1.65 0.367
Body mass index (kg/m2) 25.3 24.6 to 26.1 25.4 24.6 to 26.3 0.844
Mean arterial pressure (mm/Hg) 71.3 70.0 to 72.5 73.3 71.5 to 75.2 0.072
Ejection fraction (%) 46.5 44.7 to 48.2 47.1 45.6 to 48.5 0.585
Intubation time (hr) 5.47 5.33 to 5.62 5.32 5.18 to 5.46 0.150
Lactate (mg/dL) 23.4 25.5 to 21.4 23.0 25.0 to 21.1 0.793
pH 7.353 7.359 to 7.346 7.357 7.364 to 7.350 0.392
Base excess (mmol/L) -3.68 -3.48 to -3.89 -3.61 -3.40 to -3.81 0.606
Serum creatinine 0.89 0.93 to 0.85 0.92 0.95 to 0.87 0.426
Potassium (meq/L) 4.32 4.38 to 4.26 4.37 4.42 to 4.32 0.235
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9.86) in the insulin-metformin group. There
was no significant difference between the 2
groups (t= -0.072; P=0.943).
No significant difference was observed in
the number of high blood lactate events
(between 30-45 mg/dL) during the study in the
insulin group and the insulin-metformin group
(χ2=0.850; P=0.467) (Figure 4).
Average blood glucose of patients in both
groups decreased during the study. However,
the reduction observed in the insulin-met-
formin group was more than the insulin group
and this difference was statistically significant
(F(1, 187) =9.873; P<0.001).
Discussion and Conclusions
The study findings showed that use of met-
formin (1,000 mg/BD) together with insulin in
type 2 diabetic ICU patients after CABG surgery
did not cause lactic acidosis. Blood lactate lev-
els in both groups gradually decreased during
the study, but we observed no significant differ-
ence between the 2 groups. There was no sig-
nificant difference in blood pH between the 2
groups during the study period and mean blood
pH in patients were in the normal range (7.35-
7.45). No dangerous reduction or increase in
blood pH occurred. Some cases of lactic acido-
sis caused by metformin were reported by
Preiser and Vincet,11 Lustik et al.,12 Silvestre et
al.,13 Ashall and Dawes,14 and Cezure et al.,15
that led to stricter limits in the use of met-
formin in type 2 diabetic patients. However,
Lalau and Race16 and Kamber17 have stated that
lactic acidosis cannot be directly attributed to
metformin use. Their rationale was that many
patients who developed lactic acidosis while
taking metformin were those who suffered
from underlying problems such as heart failure,
kidney and liver diseases, and diabetes, which
are known as risk factors of lactic acidosis.
Duncan et al. showed that type 2 diabetic
patients treated with metformin would not
develop more severe acidosis. Also long-term
intubation, infection and overall morbidity in
the metformin group were significantly less
than the non-metformin group.18 In the
Duncan et al. study, serum lactate level was
measured only in patients with primary dis-
eases, while the exact dose and the last dose of
metformin were not clear and metformin was
continued up to cardiac surgery. Importantly,
the present study showed that the use of
insulin along with high-dose metformin, even
immediately after cardiac surgery, does not cre-
ate acidosis, but improves blood glucose control
in these patients.
Our results in a larger number of patients
confirmed the study by Mojtahedzadeh et al.
which showed no significant relationship
between plasma level of metformin, blood lac-
tate and pH. Also blood pH was in the normal
range and no pH less than 7.3 was seen.19 We
showed that the use of 1,000 mg metformin
twice daily plus insulin does not cause lactic
acidosis in type 2 diabetic patients, while
there was no difference in the amount of
bicarbonate prescribed to each of the 2 groups.
Importantly, no lactic acidosis occurred follow-
ing high-dose metformin in patients undergo-
ing CABG with cardiopulmonary pump who
have a higher potential risk of lactic acidosis.
Ansari showed that taking metformin with
insulin in ICU patients did not cause acidosis,
which is consistent with the results of this
study.20 Therefore, based on the current pub-
lished data and results of the present study, it
seem that metformin administration in post-
operative or critically injured patients is not
absolutely contraindicated, but rather benefi-
cial, particularly if selected for those patients
with satisfactory hepatic, renal and cardiac
function, and as long as these parameters are
appropriately monitored.21 Lactic acidosis due
to metformin is easily preventable by avoiding
dehydration, especially in concomitant
nephrotoxic drug use.22 This study showed
that high-dose metformin along with appropri-
ate monitoring of renal and liver function not
only protects against but also reduces micro-
vascular complications and deaths from car-
diovascular disease, even after coronary artery
surgery in type 2 diabetic patients.23 During
the present study, after frequent monitoring of
the patients in the ICU, a patient was exclud-
ed due to a creatinine level higher than 1.5
(UNIT) on 2 consecutive tests. On the other
hand, blood glucose level in the metformin-
insulin group was reduced more than the
Figure 1. Flow dia-
gram of patients’
r andomi z a t i on ,
intervention and
analysis.
Figure 2. Changes in
blood lactate level
(mean and SEM) of
patients in insulin
and insulin-met-
formin groups dur-
ing the study.
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insulin group. This result suggests the posi-
tive effect of metformin in the control of blood
glucose in type 2 diabetic patients undergoing
CABG surgery, which is probably due to the
metformin effect on the insulin resistance of
these patients. This is consistent with the
findings of previous studies.19
Use of metformin in type 2 diabetic ICU
patients after CABG surgery is associated with
better glucose control without theoccurrence of
lactic acidosis. Consequently, it is a safe and
effective drug and, so, a good choice for control-
ling blood glucose in order to reduce the com-
plications and improve survival in these
patients.
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